Skip to main content
. Author manuscript; available in PMC: 2014 Jul 7.
Published in final edited form as: Clin Breast Cancer. 2013 Aug;13(4):254–263. doi: 10.1016/j.clbc.2013.02.010

Table 2.

Primary Treatment Characteristics for Stage I, II, and III Patients

Variable Total (n =
124)		 Short-Term
Treatment Duration
(n = 42)		 Intermediate
Treatment Duration
(n = 43)		 Long-Term
Treatment
Duration (n = 39)		 P
Neo or Adjuvant
Chemotherapy, n (%) 		.105
 No 17
(13.7)		 4 (9.5) 10 (23.3) 3 (7.7)
 Yes 107 (86.3) 38 (90.5) 33 (76.7) 36 (92.3)
Neo or Adjuvant
Trastuzumab, n (%) 		.146
 No 91
(73.4)		 28 (66.7) 30 (69.8) 33 (84.6)
 Yes 33
(26.6)		 14 (33.3) 13 (30.2) 6 (15.4)
Adjuvant Hormonal
Therapy, n (%) 		.238
 No 58
(46.8)		 24 (57.1) 17 (39.5) 17 (43.6)
 Yes 66
(53.2)		 18 (42.9) 26 (60.5) 22 (56.4)